Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 14/20 | 0.68 |
| ▸ | GABRG2 | P18507 | 14/20 | 0.68 |
| ▸ | GABRB3 | P28472 | 14/20 | 0.68 |
| ▸ | GABRA3 | P34903 | 14/20 | 0.68 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.68 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6040543 | 0.94 | GABRA1 (0.67) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6991412 | 0.83 | GABRG2 (0.64) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL340896 | 0.83 | GABRA1 (0.78) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6040758 | 0.82 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL340810 | 0.81 | GABRG2 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL342428 | 0.81 | GABRA1 (0.55) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL341650 | 0.80 | GABRG2 (0.67) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL5799755 | 0.80 | GABRG2 (0.67) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL341811 | 0.80 | GABRA1 (0.70) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL342855 | 0.79 | GABRA1 (0.79) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960584-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2005-11-01 | — | — | US | claimed |
| US-20040116432-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME LTD. (GB) | 2004-06-17 | — | — | US | claimed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | claimed |
| WO-2002083675-A2 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-24 | — | — | WO | claimed |
| US-20060142178-A1 | Method of treating cancer | BARNETT STANLEY F | 2006-06-29 | — | — | US | disclosed |
| US-6960584-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1496981-A2 | METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040116432-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME LTD. (GB) | 2004-06-17 | — | — | US | disclosed |
| US-20040106540-A1 | Method of treating cancer | BARNETT STANLEY F (US) | 2004-06-03 | — | — | US | disclosed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | disclosed |
| WO-2003084473-A2 | METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2002083675-A2 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102360-A1 | Combination therapy | MTOR, AKT2, PLK1 | GABRA1 4513/4885GABRG2 4280/4885GABRB3 4320/4885 |
| US-20060142178-A1 | Method of treating cancer | PACSIN2, CTTN, TNK2 | GABRA1 4046/4885GABRG2 3417/4885GABRB3 2919/4885 |
| US-20040106540-A1 | Method of treating cancer | PACSIN2, CTTN, PLK1 | GABRA1 4046/4885GABRG2 3403/4885GABRB3 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.